Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
FDA rejection and regulatory status Development timeline: 2000s: Developed for Parkinson's/Alzheimer's 2008: Phase 2 obesity trials (successful) 2010: Phase 3 trials initiated 2010: Development halted due to safety concerns 2012: FDA rejected obesity indication Present: No approved indication anywhere Why FDA rejected: Cardiovascular safety concerns primary reason Increased heart rate and blood pressure Risk-benefit ratio unfavorable Safer alternatives available ( GLP-1 agonists ) Development company abandoned pursuit No current path to approval Regulatory status by country: Current legal classification: Not a controlled substance (not scheduled) Not approved for any human use Sold as "research chemical" only "Not for human consumption" labels Legal gray area (enforcement rare) See are peptides legal guide at SeekPeptides
However, glutathione is not officially FDA-approved for specific medical treatments like skin lightening or curing diseases when given as an injection
But you said you stopped dieting
Casuistry: medical nutrition intervention with specific micronutrient and exercise therapy in pancreatic cancer
The safety and efficacy of trevogrumab and garetosmab have not been evaluated by any regulatory authority
Many peptides are not FDA-approved for human use outside of limited clinical contexts
US$ 29.23
US$ 22.18
US$ 24.68
US$ 24.85
US$ 24.30
